Introduction
Patients and methods
Patients
Measures
Statistical analyses
N (%) | |||
---|---|---|---|
Group CT− a (n = 43) | Group CT+ b (n = 88) |
p Value | |
Socio-demographics | |||
Age (mean (min/max) SD) | 61 (36/79) 11.4 | 62 (36/81) 10.0 | ns |
Gender | ns | ||
Male | 19 (44) | 39 (44) | |
Female | 24 (56) | 49 (56) | |
Indication | ns | ||
Neo-adjuvant | 1 (2) | 4 (5) | |
Adjuvant | 17 (40) | 36 (41) | |
Curative | 2 (5) | 7 (8) | |
Palliative | 23 (53) | 41 (47) | |
Type of malignancy | ns | ||
Breast | 7 (16) | 13 (15) | |
Colon | 16 (37) | 29 (33) | |
Sigmoïd | 3 (7) | 9 (10) | |
Rectal | 9 (21) | 7 (8) | |
Gastric | 0 | 6 (7) | |
Non Hodgkin lymphoma | 1 (2) | 8(9) | |
Prostate | 0 | 7 (8) | |
Ovarian | 2 (5) | 5 (6) | |
Pseudo myxoma peritonei | 1 (2) | 0 | |
Lung | 0 (0) | 1 (1) | |
Endometrial | 0 (0) | 2 (2) | |
Larynx | 1 (2) | 0 | |
Multiple myeloma | 1 (2) | 0 | |
Hodgkin lymphoma | 1 (2) | 0 | |
Esophagus | 0 | 1 (1) | |
Pancreatic | 1 (2) | 0 | |
Chemotherapyc
| ns | ||
Oxaliplatin | 29 (67) | 45 (51) | |
Paclitaxel | 9 (21) | 15 (17) | |
Docetaxel | 0 | 12 (14) | |
Carboplatin | 0 | 1 (1) | |
Cisplatin | 2 (5) | 8 (9) | |
Vincristin | 2 (5) | 7 (8) | |
Vinblastin | 1 (2) | 0 |
Mean score ± SD (range) | |||
---|---|---|---|
Group CT− (n = 43) | Group CT+ (n = 88) |
p Value | |
Paresthesia upper extremity | 0.2 ± 0.5 (0–2) | 1.9 ± 1.8 (0–5) | <0.001 |
Dysesthesia upper extremity | 0.2 ± 0.7 (0–3) | 0.8 ± 1.3 (0–5) | <0.01 |
Paresthesia lower extremity | 0.3 ± 0.8 (0–3) | 1.5 ± 1.7 (0–5) | <0.001 |
Dysesthesia lower extremity | 0.2 ± 0.8 (0–4) | 1.1 ± 1.6 (0–5) | <0.001 |
Paresthesia mouth | 0.2 ± 0.7 (0–4) | 0.9 ± 1.4 (0–5) | <0.01 |
Paresthesia face | 0.1 ± 0.6 (0–4) | 0.6 ± 1.2 (0–5) | <0.001 |